Niemann Pick C disease is a rare, neurodegenerative, lipid storage disorder. Approximately 95% of the disease is caused by mutations in NPC1, a late endosomal membrane protein that functions in export of lipoprotein-derived cholesterol. The most prevalent NPC1 mutation, I1061T, produces a protein that is misfolded and rapidly degraded. Histone deacetylase inhibitors (HDACi) recently have been shown to reduce the accumulation of cholesterol and other lipids found in patient cells harboring the NPC1I1061T and other mutations. This beneficial effect is associated with decreased endoplasmic reticulum-associated degradation and enhanced delivery of the mutant NPC1 proteins to late endosomes and lysosomes. With the recent generation in our laboratory of a humanized mouse model in which the I1061T mutation knocked into the murine NPC1 locus, it is possible to examine the effect of HDACi on NPC1 stability in vivo. We hypothesize that treatment with an HDACi in the NPC1I1061T knockin model of NPC1 disease will increase levels of the mutant NPC1I1061T protein, slowing progression of neurodegeneration and prolonging survival. The therapeutic potential of HDACi for treatment of NPC1 disease is being explored in through a collaboration involving pharmaceutical partners and an HDACi collaborative involving investigators from NIH (NICHD/NCATS), Weill Cornell Medical College, University of Notre Dame, Albert Einstein College of Medicine, and Washington University, along with the Ara Parseghian Medical Research Foundation. The goals of this proposal are to identify orally-available, CNS-penetrant HDAC-selective compounds using cell-based screens; to evaluate in vivo in the NPC1I1061T knockin model candidate HDACi compounds; and to develop effective therapeutic regimens for testing of the HDACi in clinical trials. The proposed in vivo studies further will provide valuable data for initial dosing protocols and biomarker monitoring in future human trials.
Niemann-Pick C (NPC) disease is a rare, neurodegenerative disorder, characterized by progressive impairment of motor and intellectual function. Children affected by this disorder show symptoms in early childhood, and usually die in adolescence. There are no FDA-approved therapies for this disorder. This project will address the unmet needs of the NPC disease community by testing a new class of drugs, known as histone deacetylase inhibitors, in a mouse model of NPC disease. As these drugs have been shown to improve brain function in multiple disease models, advancing this drug development program for NPC disease may prove useful for more common disorders.
|Rabe, Jan-Hinrich; A Sammour, Denis; Schulz, Sandra et al. (2018) Fourier Transform Infrared Microscopy Enables Guidance of Automated Mass Spectrometry Imaging to Predefined Tissue Morphologies. Sci Rep 8:313
|Pipalia, Nina H; Subramanian, Kanagaraj; Mao, Shu et al. (2017) Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells. J Lipid Res 58:695-708
|Munkacsi, Andrew B; Hammond, Natalie; Schneider, Remy T et al. (2017) Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat. J Biol Chem 292:4395-4410
|Miyake, Yasuyuki; Keusch, Jeremy J; Wang, Longlong et al. (2016) Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat Chem Biol 12:748-54
|Grigalunas, Michael; Wiest, Olaf; Helquist, Paul (2016) Single-Flask Multicomponent Synthesis of Highly Substituted ?-Pyrones via a Sequential Enolate Arylation and Alkenylation Strategy. Org Lett 18:5724-5727